In the few years since their introduction into clinical practice the 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase inhibitors, or statins, have captured the market for cholesterol lowering drugs. They display virtually all the attributes of the ideal hypolipidaemic agent. Total plasma cholesterol falls by 15-30% and low density lipoprotein (LDL) cholesterol by 20-40% while high density lipoprotein (HDL) cholesterol rises by 5 4 Plasma triglyceride concentrations therefore fall precipitously (by 50% or more) during treatment, and this is accompanied by important qualitative reductions in the atherogenicity of LDL and increases in the cardioprotection offered by HDL. The complementarity of these effects with the cholesterol lowering actions of the statins argues for the combined use of these drugs in the treatment of patients with increases in both cholesterol and triglyceride, the most common lipid abnormality seen in individuals with existing coronary heart disease. Analysis of a score of such published studies in 516 patients over the past five years shows that consistent clinically useful gains in the reduction of total cholesterol, triglyceride, and LDL cholesterol and an increase in HDL (compared with either agent used separately) when statins and fibrates are used in combination.5 Most of these studies featured gemfibrozil combined with lovastatin: but simvastatin has also been used with gemfibrozil, bezafibrate, and fenofibrate; and pravastatin has been used with gemfibrozil and bezafibrate. But do the lipid lowering benefits of the combination offset the potential risks of treatment? Each drug class on its own has been shown to be both acceptable to patients and very safe. None the less, both have been linked individually to myopathy; and in combination6 they may increase the risk of this adverse event.
A review of the myopathic incidents that were recorded in the 20 studies discussed above shows that serum creatine kinase, used as a surrogate for muscle damage, was rarely increased. 
